China NMPA Medical Device Registration Local Agent Service
For an overseas medical-device applicant or filer, China’s NMPA framework requires a designated enterprise legal person in China to act as the local agent for registration or filing matters. The appointment is more than a filing convenience: the agent is the regulated China-side interface that assists the overseas registrant or filer with defined lifecycle duties. The overseas registrant or filer, however, remains responsible for the medical device and does not transfer its core regulatory responsibility merely by appointing an agent.
When a China NMPA local agent is required
Under the current medical-device registration rules, an overseas applicant or filer must designate an enterprise legal person established in China as its agent. For imported Class I devices, the China-side entity handles the filing submission; for imported Class II and III devices, the designated China entity submits the registration materials on behalf of the overseas applicant. The rule therefore concerns the status and formal designation of the China entity, not simply whether a distributor, consultant or affiliate happens to be involved commercially.
- Eligible form: the agent must be an enterprise legal person in China under the cited NMPA registration framework.
- Formal role: the entity must be designated by the overseas applicant or filer for the relevant registration or filing relationship.
- Responsibility split: the overseas registrant or filer retains its statutory product responsibilities; the China agent assists with the duties assigned to it by the regulations.
Registrant, NMPA agent, consultant and distributor are different roles
Keeping these roles separate prevents a common governance error: assuming that the party filing documents automatically owns every commercial or regulatory function in China.
| Role | Regulatory position | Typical function | Boundary to keep clear |
|---|---|---|---|
| Overseas registrant or filer | Product-side responsible party | Maintains quality, safety, post-market and other statutory responsibilities for the device | Appointment of an agent does not remove these responsibilities |
| China NMPA agent | Designated enterprise legal person in China | Handles registration/filing interface and assists with prescribed lifecycle duties | Is not automatically the distributor, importer, consultant or registration owner |
| Regulatory consultant | Advisory/service role | Supports classification, evidence planning, dossier strategy and project management | Advisory work does not by itself satisfy the formal agent designation requirement |
| Distributor/importer | Commercial/supply-chain role | Imports, distributes or sells under the licences and controls applicable to that activity | Commercial appointment alone does not make it the NMPA agent |
What the agent appointment and operating mandate should cover
The regulations establish the legal role; the contract and operating procedures should make that role executable. A workable mandate normally allocates records, access, response times and decision rights rather than merely naming an entity.
- the exact registrant/filer and device registrations or filings covered by the mandate;
- authority to submit, receive and relay NMPA communications and required updates;
- access to the current registration dossier, Chinese translations and source-language documents where applicable;
- procedures for complaint, adverse-event, recall, corrective-action and re-evaluation information exchange;
- support for regulatory inspections and access to records needed for China-side coordination;
- UDI and other regulatory data-maintenance responsibilities that are assigned to the agent;
- exit, handover, record-return and transition obligations if the agent changes.
Registration and filing documents are required in Chinese. Where documents are translated from a foreign language, the registration rules also require the original foreign-language documents to be provided. The practical workflow should therefore control both the authoritative source files and the Chinese submission versions.
Practical local-agent workflow
- Confirm the role. Identify the overseas applicant/filer, the intended China agent and the specific devices/filings covered.
- Verify entity eligibility. Confirm that the proposed agent is the required China enterprise legal person and that its corporate details are suitable for the filing relationship.
- Map responsibility and access. Agree who supplies source evidence, translations, signatures, regulatory records and post-market information.
- Execute the designation and filing interface. Put the appointment documentation in place and align it with the NMPA registration or filing submission.
- Run controlled communications. Track authority questions, supplements, decisions and post-approval notices through a shared regulatory log.
- Maintain the lifecycle relationship. Keep adverse-event, quality, inspection, change-control and regulatory-data processes active after market entry.
This page owns the local-representation layer. The complete classification, testing and dossier pathway belongs to the separate China NMPA medical device registration service page, while strategic gap analysis belongs to the China NMPA medical device registration consultant page.
The local-agent role continues after registration or filing
| Lifecycle area | China-agent involvement | What the overseas registrant/filer must still control |
|---|---|---|
| Adverse-event monitoring | The designated agent undertakes monitoring work for imported devices sold in China and supports reporting/information transfer under the applicable measures | Maintain the overseas holder’s monitoring system, decisions and cooperation with the China agent |
| Quality-system reporting | Current manufacturing-supervision rules provide for the imported registrant/filer to entrust the agent to submit the annual quality-management-system self-inspection report to the relevant provincial authority | Prepare and maintain an adequate quality system and truthful underlying report information |
| Overseas inspection | The agent is responsible for coordination and cooperation when NMPA conducts an overseas inspection of imported-device manufacturing | Make the overseas site, records and responsible personnel available as required |
| Recall and risk control | Supports China-side communication, traceability and execution of required measures | Take product-risk decisions and fulfil the registrant/filer’s statutory recall and risk-control duties |
| Regulatory data / UDI | Maintains China-side regulatory data where the applicable system assigns that task to the agent | Supply accurate, current product information and approve controlled changes |
Liability boundaries matter when selecting an agent
China’s Medical Device Regulations expressly impose duties on the designated domestic enterprise legal person and provide administrative consequences if it fails to perform the relevant obligations. Article 98 provides for an order to correct and a warning, with a fine of RMB 50,000–100,000; in serious cases the fine can be RMB 100,000–500,000, and specified responsible personnel can be barred for five years from medical-device production and distribution activities. This is one reason the appointment should be treated as a regulated operating relationship rather than a nominal address service.
At the same time, those agent-side consequences do not convert the agent into the product registrant. The overseas registrant or filer remains responsible for the statutory duties allocated to it, including quality-system, post-market, traceability and recall obligations.
Changing the China agent requires a controlled handover
A change of agent should be planned around regulatory records and continuity, not only contract termination. NMPA’s UDI guidance specifically provides a mechanism for a new agent to request an agent change in registration/filing certificate information and, after approval, maintain the corresponding UDI data. Other records and submissions must be reviewed according to the device and the change being made.
- inventory every registration, filing, UDI record, open authority request and post-market case tied to the outgoing agent;
- appoint the replacement entity and document its authority before operational cut-over;
- submit the required agent-change/update actions in the relevant NMPA systems;
- transfer dossiers, correspondence, adverse-event records, complaint/recall data and access credentials under controlled procedures;
- verify that regulator-facing contact data and ongoing reporting responsibilities now point to the new agent;
- retain an auditable handover record and confirm that no open regulatory obligation was lost in transition.
Agent due-diligence checklist
| Question | Why it matters | Evidence to request |
|---|---|---|
| Is the entity the required China enterprise legal person? | Eligibility is a regulatory threshold, not a marketing claim | Corporate registration details and exact legal name |
| Will it accept the formal NMPA agent designation? | A consultancy or distribution contract alone is not the designation | Draft appointment/mandate and responsibility schedule |
| Who controls the regulatory account, records and correspondence? | Loss of access can create transition and compliance risk | Access matrix, record-retention rules and export/handover procedure |
| How are adverse events and recalls escalated? | Post-market duties require reliable two-way information transfer | Written SOP, escalation contacts and response workflow |
| How will inspections and QMS reporting be supported? | The agent has defined coordination/reporting functions | Inspection protocol, annual-report calendar and document responsibilities |
| What happens if the relationship ends? | Regulatory continuity must survive a commercial dispute or vendor change | Exit clause, data-return obligation, transition assistance and credential-transfer terms |
What this local-agent page does not replace
Choosing and governing the China agent is only one layer of market access. It does not determine the device classification, clinical/testing evidence, full dossier route or every licence needed by companies that import or distribute the product. For end-to-end filing execution, use the registration service; for pre-filing strategy and gap assessment, use the registration consultant; for a broader country-level route map, use product compliance and market access services in China.
Official sources
- Regulations for the Supervision and Administration of Medical Devices (SAMR)
- Provisions for Medical Device Registration and Filing (NMPA English)
- Measures for Medical Device Adverse Event Monitoring and Re-evaluation (NMPA English)
- Provisions for the Supervision and Administration of Medical Device Manufacturing (NMPA English)
- Provisions for Medical Device Manufacturing Supervision — annual QMS self-inspection reporting (NMPA English)
- NMPA UDI FAQ
FAQ
Can our Chinese subsidiary act as the NMPA agent?
Potentially yes, if it is an enterprise legal person in China and is formally designated for the overseas applicant/filer’s registration or filing relationship. Group ownership by itself is not the appointment; the regulated role and responsibilities still need to be documented.
Can the distributor be the local agent?
The same legal entity can perform more than one function if the applicable requirements for each function are met, but distribution status does not automatically make it the NMPA agent. Keep the regulatory-agent mandate and the commercial distribution arrangement distinguishable.
Does appointing an agent transfer the overseas registrant/filer’s NMPA regulatory responsibilities to the China agent?
No. The designated China agent has its own statutory duties and can face consequences for failing them, but the overseas registrant or filer remains responsible for the statutory duties the regulations place on the registrant/filer.
Does the agent only matter until the registration certificate is issued?
No. The role continues into post-market work, including China-side adverse-event monitoring, regulatory information exchange, inspection coordination and other lifecycle tasks assigned by the applicable rules.
Can we change agents after registration?
Yes, but the transition should be handled as a regulated change and records handover. NMPA’s UDI guidance expressly addresses an agent-change request and transfer of subsequent UDI maintenance to the new agent after approval; the company should also review all other affected registration, filing and post-market records.
Does an NMPA agent replace a registration consultant?
No. The agent is the formally designated China-side legal entity for the overseas applicant/filer. A consultant may advise on classification, evidence and dossier strategy, but advisory support alone does not satisfy the formal agent role.